Brain-derived neurotrophic factor and the derived dodecapeptide function as Toll-like receptor 4 antagonists in acute lung injury.

Summary

Epithelial-derived BDNF is diminished in ALI and inversely correlates with inflammation. BDNF directly binds and antagonizes macrophage TLR4; a minimal BDNF-derived dodecapeptide preserves anti-inflammatory activity in vitro and in vivo without pro-proliferative effects, nominating BDP-12 as a therapeutic candidate for acute inflammatory lung diseases including sepsis-related injury.

Key Findings

• BDNF levels are reduced in pulmonary epithelial cells during ALI and inversely correlate with inflammatory responses.
• Augmenting BDNF alleviates inflammatory lung injury, but effects are abolished in macrophage-deleted mice, implicating macrophages.
• Proteomics identified macrophage TLR4 as a direct binding partner of BDNF; the aa104–115 fragment is essential for this interaction.
• A synthetic BDNF-derived dodecapeptide (BDP-12) retains TLR4 antagonism and anti-inflammatory effects in vitro and in vivo without pro-proliferative side effects.

Clinical Implications

Targeting TLR4 with a BDNF-derived minimal peptide (BDP-12) could offer a novel anti-inflammatory strategy for acute inflammatory lung diseases, potentially including sepsis-related acute lung injury and acute respiratory distress syndrome.

Limitations

• Preclinical findings; human validation and pharmacokinetics of BDP-12 are unknown
• Optimal dosing, delivery route, and long-term safety were not addressed

Future Directions

Evaluate BDP-12 pharmacokinetics, safety, and efficacy in large-animal models, followed by early-phase clinical trials in acute inflammatory lung diseases and sepsis-related lung injury.